GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
W

Walvax Biotechnology Co 300142.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

11.31

-1.22%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Walvax Biotechnology Co

Its shares trade on Shenzhen under the ticker 300142.SZ. It has been listed since 12 November 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.41bn and net income of CN¥177.7m. At that date it held total assets of CN¥12.07bn and shareholders' equity of CN¥8.62bn.

Walvax Biotechnology Co., Ltd. engages in the research and development, production, and sale of biopharmaceutical products. The company is headquartered in Kunming, Yunnan. The company went IPO on 2010-11-12. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The firm distributes its products mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
12 Nov 2010
Employees
1,866
Website
walvax.com ↗

Leadership

Pay as last reported

  • Mr. Yunchun LiChairman of the Board, Acting Secretary of the Board, since 2009CN¥2.8m
  • Mr. Wei YaoPresident, Staff Elected Director, since 2016CN¥1.8m
  • Mr. Shaozhong DongVice Chairman of the Board, since 2022CN¥2.0m
  • Mr. Changxiong WuChief Financial OfficerCN¥313,200
  • Mr. Qingtang DuanVice PresidentCN¥1.1m
  • Ms. Wei LiVice President
  • Mr. Yuran LiuVice PresidentCN¥1.1m
  • Ms. Yunyan WuVice PresidentCN¥1.1m
  • Mr. Yongwu FanDirectorCN¥120,000
  • Mr. Runsheng JiangDirector, since 2016CN¥2.6m
  • Ms. Ting YanStaff Elected DirectorCN¥234,000
  • Mr. Ganghong SunIndependent DirectorCN¥120,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
76
Environment
89
Social
99
Governance
40
Direct emissions (scope 1)
7,643.23 t
Energy emissions (scope 2)
34,859.04 t
Women in the workforce
55.38%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Walvax Biotechnology Co Ltd has several notable strengths that contribute to its competitive advantage:

Weaknesses

  • Despite its strengths, Walvax Biotechnology faces certain weaknesses that could hinder its growth and success:

Opportunities

  • Walvax Biotechnology can capitalize on the following opportunities to expand its business and sustainability:

Threats

  • Walvax Biotechnology should be aware of the following threats that could pose challenges to its operations and sustainability:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.